Novo Nordisk A/S

NYSE

Market Cap.

334.54B

Avg. Volume

9.24M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Novo Nordisk A/S

Novo Nordisk A/S News

Novo Nordisk A/S Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareDrug Manufacturers - General
novonordisk.com

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S Earnings & Revenue

Novo Nordisk A/S Financials

Table Compare

Compare NVO metrics with:

   

Earnings & Growth

NVO

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

NVO

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

NVO

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

NVO

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Novo Nordisk A/S Income

Novo Nordisk A/S Balance Sheet

Novo Nordisk A/S Cash Flow

Novo Nordisk A/S Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Novo Nordisk A/S Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

3.1139

Payment DateDividendFrequency
2025-04-080.78742Quarterly
2024-08-260.51264Quarterly
2024-04-020.92985Quarterly
2023-08-290.884Quarterly
2023-04-041.189Quarterly

Novo Nordisk A/S Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Novo Nordisk A/S Executives

NameRole
Mr. Lars Fruergaard JorgensenPresident, Chief Executive Officer & Member of Management Board
Mr. Henrik Ehlers WulffExecutive Vice President of Product Supply, Quality & IT and Member of the Management Board
Mr. Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer & Member of the Management Board
Ms. Camilla SylvestExecutive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board
Dr. Martin Holst LangeExecutive Vice President of Development & Member of the Management Board
NameRoleGenderDate of BirthPay
Mr. Lars Fruergaard JorgensenPresident, Chief Executive Officer & Member of Management BoardMale19664.73M
Mr. Henrik Ehlers WulffExecutive Vice President of Product Supply, Quality & IT and Member of the Management BoardMale19701.89M
Mr. Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer & Member of the Management BoardMale19711.87M
Ms. Camilla SylvestExecutive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management BoardFemale19721.84M
Dr. Martin Holst LangeExecutive Vice President of Development & Member of the Management Board19701.79M

Discover More

Streamlined Academy

Novo Nordisk A/S

NYSE

Market Cap.

334.54B

Avg. Volume

9.24M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Novo Nordisk A/S News

Novo Nordisk A/S Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Novo Nordisk A/S Earnings & Revenue

Novo Nordisk A/S Income

Novo Nordisk A/S Balance Sheet

Novo Nordisk A/S Cash Flow

Novo Nordisk A/S Financials Over Time

Novo Nordisk A/S Executives

NameRole
Mr. Lars Fruergaard JorgensenPresident, Chief Executive Officer & Member of Management Board
Mr. Henrik Ehlers WulffExecutive Vice President of Product Supply, Quality & IT and Member of the Management Board
Mr. Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer & Member of the Management Board
Ms. Camilla SylvestExecutive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board
Dr. Martin Holst LangeExecutive Vice President of Development & Member of the Management Board
NameRoleGenderDate of BirthPay
Mr. Lars Fruergaard JorgensenPresident, Chief Executive Officer & Member of Management BoardMale19664.73M
Mr. Henrik Ehlers WulffExecutive Vice President of Product Supply, Quality & IT and Member of the Management BoardMale19701.89M
Mr. Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer & Member of the Management BoardMale19711.87M
Ms. Camilla SylvestExecutive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management BoardFemale19721.84M
Dr. Martin Holst LangeExecutive Vice President of Development & Member of the Management Board19701.79M

Novo Nordisk A/S Insider Trades

No data available

DateNameRoleTransactionTypeShares

No data available

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
novonordisk.com

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Novo Nordisk A/S

Novo Nordisk A/S Financials

Table Compare

Compare NVO metrics with:

   

Earnings & Growth

NVO

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

NVO

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

NVO

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

NVO

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Novo Nordisk A/S Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

3.1139

Payment DateDividendFrequency
2025-04-080.78742Quarterly
2024-08-260.51264Quarterly
2024-04-020.92985Quarterly
2023-08-290.884Quarterly
2023-04-041.189Quarterly

Novo Nordisk A/S Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)